**Eduard Ayuso***obtained his degree in Veterinary Medicine in 2001 and his PhD in Biochemistry and Molecular Biology in 2006 obtained both at the Autonomous University of Barcelona. Dr Ayuso is an expert in several viral vector platforms for gene therapy, such as adenoviral vectors, helper-dependent adenoviral vectors and adeno-associated vectors. He has made significant contributions to the field of in vivo gene transfer in small and large animal models particularly in metabolic diseases. His training in viral vectors included stays at the University of Ulm (Germany), the International Centre for Genetic Engineering and Biotechnology (Trieste, Italy) and the Children’s Hospital of Philadelphia (USA). Also, Dr Ayuso has participated in several academic research programs in partnership with pharmaceutical and biotechnology companies.* *He is the scientific director of the translational vector core at the University of Nantes and belongs to the scientific advisory board of the Veterinary School of Nantes. Dr Ayuso publication track includes >40 peer-reviewed articles and 6 patents. In 2013, he moved to the Institut National de la Santé et de la Recherche Médicale (INSERM, UMR1089) in Nantes (France) and obtained a tenure position to lead the “Innovative Vectorology” team with the main mission of improving the efficacy and safety of recombinant adeno-associated vectors for clinical gene transfer. He is the vice-president of the French Gene and Cell Therapy Society, member of the “translational science and drug product development committee” of the American Society of Gene and Cell therapy and is a key contributor of the AAV Reference Standard Material Working Group.*